Literature DB >> 21894028

UK Renal Registry 13th Annual Report (December 2010): Chapter 1: UK RRT incidence in 2009: national and centre-specific analyses.

Julie Gilg1, Clare Castledine, Damian Fogarty, Terry Feest.   

Abstract

INTRODUCTION: This chapter describes the characteristics of adult patients starting renal replacement therapy (RRT) in the UK in 2009 and the acceptance rates for RRT in Primary Care Trusts and Health Boards (PCT/HBs) in the UK.
METHODS: The basic demographics and clinical characteristics are reported on patients starting RRT from all UK renal centres. Late presentation, defined as time between first being seen by a nephrologist and start of RRT being <90 days was also studied. Age and gender standardised ratios for acceptance rates in PCT/HBs were calculated.
RESULTS: In 2009, the incidence rate in the UK and England was 109 per million population (pmp). Acceptance rates in Scotland (104 pmp), Northern Ireland (88 pmp) and Wales (120 pmp) had all fallen although Wales still remained the country with the highest acceptance rate. There were wide variations between PCT/HBs with respect to the standardised ratios. The median age of all incident patients was 64.8 years (IQR 50.8, 75.1). For transplant centres this was 63.0 years (IQR 49.0, 74.2) and for non-transplanting centres 66.3 years (IQR 52.6, 75.9). The median age for non-Whites was 57.1 years. Diabetic renal disease remained the single most common cause of renal failure (25%). By 90 days, 69.1% of patients were on haemodialysis, 17.7% on peritoneal dialysis, 6.7% had had a transplant and 6.5% had died or stopped treatment. The mean eGFR at the start of RRT was 8.6 ml/min/1.73 m2 which was similar to the previous two years. Late presentation (<90 days) has fallen from 27% in 2004 to 19% in 2009. There was no relationship between social deprivation and presentation pattern.
CONCLUSIONS: Acceptance rates have fallen in Northern Ireland, Scotland and Wales whilst they have plateaued in England over the last four years. Wales continued to have the highest acceptance rate of the countries making up the UK.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2011        PMID: 21894028     DOI: 10.1159/000331741

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  8 in total

1.  The angiotensin-I converting enzyme gene I/D variation contributes to end-stage renal disease risk in Chinese patients with type 2 diabetes receiving hemodialysis.

Authors:  Ming Lu; Jianzhong Zhang; Ming Li; Xiaoxu Ge; Xu Dai; Jiao Zhao; Mingzhou Fu; Tao Wang; Xiyao Fang; Can Li; Rong Zhang; Weijing Zhao; Taishan Zheng; Feng Wang; Ming Yu; Tao Lei; Niansong Wang; Yuqian Bao; Limei Liu; Yanjun Liu; Weiping Jia
Journal:  Mol Cell Biochem       Date:  2016-09-16       Impact factor: 3.396

2.  East Meets West: Harmony but Not Uniformity.

Authors:  Zhi-Hong Liu
Journal:  Kidney Dis (Basel)       Date:  2015-04-30

3.  Transposition of brachiobasilic arteriovenous fistulae: improving the cosmetic effect without compromising patency.

Authors:  David van Dellen; Muneer Junejo; Hussein Khambalia; Babatunde Campbell
Journal:  Ann R Coll Surg Engl       Date:  2016-01       Impact factor: 1.891

4.  Arg913Gln of SLC12A3 gene promotes development and progression of end-stage renal disease in Chinese type 2 diabetes mellitus.

Authors:  Rong Zhang; Langen Zhuang; Ming Li; Juan Zhang; Weijing Zhao; Xiaoxu Ge; Yating Chen; Feng Wang; Niansong Wang; Yuqian Bao; Limei Liu; Yanjun Liu; Weiping Jia
Journal:  Mol Cell Biochem       Date:  2017-07-25       Impact factor: 3.396

Review 5.  Nephrology in china.

Authors:  Zhi-Hong Liu
Journal:  Nat Rev Nephrol       Date:  2013-07-23       Impact factor: 28.314

Review 6.  When to initiate renal replacement therapy: The trend of dialysis initiation.

Authors:  Ze-Hua Lin; Li Zuo
Journal:  World J Nephrol       Date:  2015-11-06

7.  Epidemiology and aetiology of dialysis-treated end-stage kidney disease in Libya.

Authors:  Wiam A Alashek; Christopher W McIntyre; Maarten W Taal
Journal:  BMC Nephrol       Date:  2012-06-08       Impact factor: 2.388

8.  Peritoneal dialysis and in-centre haemodialysis: a cost-utility analysis from a UK payer perspective.

Authors:  Catrin Treharne; Frank Xiaoqing Liu; Murat Arici; Lydia Crowe; Usman Farooqui
Journal:  Appl Health Econ Health Policy       Date:  2014-08       Impact factor: 2.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.